Rating agency CRISIL Rating revised Epigral Limited, India's leading integrated chemical manufacturer's, long term outlook to CRISIL AA- with a Positive outlook, from Stable outlook. The Short-term rating of the company has been reaffirmed at CRISIL A1+.
This revision in outlook by CRISIL highlights the company's testament to the company's dedicated efforts to position itself among the world's largest specialty chemical manufacturers. The company is well known for its robust financial and operational performance.
The company recently announced the expansion project of CPVC and Epichlorohydrin (ECH). CPVC resin capacity will be expanded to 1,50,000 TPA (Tonnes Per Annum) by adding another 75,000 TPA capacity and Epichlorohydrin (ECH) capacity will be enhanced to 1,00,000 TPA by adding another 50,000 TPA capacity, at Epigral's Dahej facility in Gujarat. This will elevate the company's CPVC resin capacity to the largest resin facility in the world and Epichlorohydrin will be the largest facility in India. These are in line with Epigral's vision of focusing on import substitute chemical products aligning with the Government of India's initiative of Aatmanirbhar Bharat and Make in India.
In its recently released Q2FY 25 results, Epigral reported a remarkable growth of 111% in Profit After Tax (PAT), alongside a significant increase in quarterly revenue, which rose by 32% to Rs 632 crores in the quarter ending September. Also, net Debt/EBITDA improved continuously to 1.4x as on 30th September 2024 compared to 1.8x as on 30th September 2023.
Shares of Meghmani Finechem Ltd was last trading in BSE at Rs. 1968.80 as compared to the previous close of Rs. 2005.30. The total number of shares traded during the day was 7082 in over 1381 trades.
The stock hit an intraday high of Rs. 2006.00 and intraday low of 1920.00. The net turnover during the day was Rs. 13835038.00. |
